Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


McClellan’s FDA Legacy? Decisive Role In Product Development Priorities

This article was originally published in The Gray Sheet

Executive Summary

FDA's "critical path" initiative to help streamline R&D costs and product development schedules is positioning the agency to eventually seek grant-making authority from Congress

Related Content

CDRH “Innovation Initiative” Highlights Efforts To Speed Premarket Process
CBER’s Goodman Eyes Tissue, Blood Test Innovation Through Post-9/11 Lens
On FDA Critical Path, Device Industry Demands Independence From Pharma
FDA Critical Path Office Would Define Up To Four “Opportunities” Per Year
CDRH Keeps An Eye On Needle-Free Injector Policy Development
CDRH Promotes Bayesian Tool To Speed Approvals; Statistical Rigor Required
FDA Science Board Previews Device “Critical Path” R&D Opportunity List
Device Review Templates Are Milestones On Road To “Critical Path” – CBER
Imaging Subgroup Formed Under NCI/FDA Oncology Task Force
Interdisciplinary Teams Focused On Imaging Research Needed – NIH Director



Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts